glucagon receptor retatrutide How works: mechanism of action and onset explained retatrutide mechanism triple agonist glp-1

In a 48-week phase 2 study of retatrutide involving 338 overweight or obese non-diabetic participants, researchers observed dose-dependent decreases in weight and improvements in waist circumference, blood pressure, levels of glycated hemoglobin, fasting glucose and insulin, and most lipid metrics

They forget lunch

Side effects cluster heavily in weeks 5 through 10, coinciding with dose escalation through the most sensitive adaptation period

February 4, 2026

At the end of the week, appetite suppression was still pretty strong and I felt like I couldnt really eat normal-sized meals (equivalent of the previous week on day 2-3)

doi: 10.1001/jama.2021.23619